All News
Treatments Do Not Increase Infection Risk in Ankylosing Spondylitis
A large Canadian study of the drug use in ankylosing spondylitis (AS) demonstrated no evidence that the risk of serious, hospitalized infection was influenced by the use of DMARD and/or of tumour necrosis factor inhibitors (TNFi) therapy.
Read Article
Dietary Recommendations for Psoriatic Disease
A systematic review by the Medical Board of the National Psoriasis Foundation examined the role of diet in managing adult patients with psoriasis and/or psoriatic arthritis and suggest that dietary interventions to reduce disease severity.
Read Article
The RheumNow Week in Review – We’re Number One! (8.17.18)
Dr. Cush reviews the articles and news from the last week on RheumNow.com. Information on comorbidities, the downside of steroids, unmet need in psoriatic arthritis, and the top 10 rheumatology programs.
Read Article
Managing Comorbidity and Poor Drug Responses
Comorbidity is pervasive and complicates medical care in general. It can be a by-product of aging. It may result from drug therapy or an inciting disease process and may be part of the constellation that defines the primary disorder. A growing body of evidence that suggests that comorbidity has a significant dampening effect on drug responsiveness and, adds to poorer outcomes in patients with inflammatory arthritis.
Read Article
Back Pain in Psoriatic Arthritis
A single center study of psoriatic arthritis patients has shown that rheumatologist-judged inflammatory back pain (IBP) and criteria defining IBP may not perform well when ascertaining axial involvement in PsA patients.
Read Article
Higher Infection Rates for Infliximab in Psoriasis
A prospective study of psoriasis patients from the British Association of Dermatologists Biologic Interventions Register demonstrated that infliximab therapy yielded 2-3 times more serious infection than seen in those treated with non-biologic DMARDs or methotrexate (MTX).
Read Article
The Fate of Palindromic Rheumatism
Palindromic rheumatism (PR) is an intermittent inflammatory arthropathy with episodes of arthritis and/or periarticular inflammation that wax and wane over time. It is thought that up to one-third of such patients may go on to develop rheumatoid arthritis (RA).
Read Article
Minimal Disease Activity: The Goal in PsA
The majority of patients with psoriatic arthritis (PsA) who achieved a state of minimal disease activity (MDA) after 6 months of treatment with adalimumab (Humira) maintained that response through 24 months, a large observational study found.
Read Article
The RheumNow Week in Review – Cocoon Therapy? (7.20.18)
Dr. Jack Cush reviews highlights from the news and social media on RheumNow.com in the past week.
Read Article
Predictors of Methotrexate Non-Response
New research from a UK study suggests that nonresponse to oral or subcutaneous MTX was seen in 43% and is predicted by seronegativity, higher disease activity measures and higher anxiety scores.
Read Article
The RheumNow Week in Review –Fateful Outcomes in Rheumatology (7.13.18)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. Fateful outcomes in Rheumatology, what happens to Seronegatives, IL-23 fails, MRI progression, Not all inflammatory back pain becomes SpA:
Read Article
Defining Refractory RA by Biologic Use
A study from the British Society for Rheumatology Biologics Register (BSRBR) has shown that biologic refractory disease is seen in at least 6% of patients who have ever received a biologic DMARD (bDMARDs).
Read Article
Liver Disease Increased in Psoriasis
An observational case-control study has shown that psoriasis is associated with an increased prevalence of nonalcoholic fatty liver disease (NAFLD).
Read Article
IL-23 Inhibitor Fails in Ankylosing Spondylitis
A study of the IL-23 risankizumab in active ankylosing spondylitis (AS) patients failed to show efficacy and did not meet primary efficacy endpoints in a 6-month trial.
Read Article
Best of 2017: Cause of Death in Ankylosing Spondylitis
A French population based study of ankylosing spondylitis (AS) was report in the Journal of Rheumatology.
They analyzed the death certificates and cause of death in 2940 AS patients over 3 different decades (1969-78; 1979-99; 2000-2009).
Read Article
The RheumNow Week in Review – Life Savers for Rheumatologists (6.29.18)
Dr. Jack Cush reviews selected news and journal reports from the past week on RheumNow.com.
Read Article
Ixekizumab Effective in Ankylosing Spondylitis
Eli Lilly announced today the results of the COAST-W trial showing that ixekizumab (Taltz) was effective in a Phase 3 study Ankylosing Spondylitis (AS) patients who had an inadequate response or intolerance to tumor necrosis factor (TNFi) inhibitor therapy.
Read Article
NPF Dietary Recommendations for Psoriatic Disease
The National Psoriasis Foundation has released dietary recommendations for adults with psoriasis and psoriatic arthritis, based on a systematic review of the current literature, with the strongest focus on weight reduction for those who are overweight or obese.
Read Article
Five Barriers to Biosimilar Adoption in the US
A recent Deloitte analysis of the biosimilar market in the USA suggests there are defined obstacles to biosimilar use that must be dealt with, especially as the current administration is seeking to lower drug prices and reduce out-of-pocket costs for US consumers.
Read Article
Enthesitis in PsA: A New Focus of Treatment?
Patients with psoriatic arthritis (PsA) whose disease manifestations include enthesitis showed significantly greater responses to interleukin (IL)-23 inhibition than to blocking tumor necrosis factor (TNF), suggesting the possibility that treatment decisions in the future might be guided by speci
Read Article
